Windtree Therapeutics Inc (WINT) Quote

WINT........................................................................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783

WINT EXPLOSION

WINT POST SPLIT MOVE

WINT, new 52 week low

RS info -1 for 50- feb 20--Windtree Therapeutics, Inc. (NasdaqCM: WINT) (“Windtree” or the “Company”), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, announces that its board of directors has approved a 1-for-50 reverse stock split of the Company’s common stock. The Company’s stockholders approved the reverse stock split proposal at the Company’s Special Meeting of Stockholders held on February 3, 2025. The stockholders granted the board of directors the authority to determine the exact split ratio and when to proceed with the reverse stock split.
The reverse stock split will become effective on February 20, 2025 at 5:00 p.m., Eastern Time (the “Effective Time”), and the Company’s common stock is expected to begin trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market (“Nasdaq”) on February 21, 2025 at market open under the existing ticker symbol, “WINT.” The reverse stock split is intended to increase the price per share of the Company’s common stock to allow the Company to demonstrate compliance with the $1.00 minimum bid price requirement for continued listing on Nasdaq, among other benefits.

big uptick on GNS also 😅

nice move 😁

WINT.............................................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783

.2530 + 58%

Jumped in today .125 heavy

great site- thanks RS 5 to 50 Vote Approved

Scroll 9 down...https://dilutiontracker.com/app/reverse-split

RS approved- no ratio announced yet

$WINT Hmm reversal here starting? Maybe run before 2/3 meeting.

checked for reason on surge and nothing visible, even on website

today announced that Alexandre Mebazaa, MD, one of the world’s recognized leaders in cardiogenic shock, gave a well-received presentation highlighting the data on istaroxime from the recently completed Phase 2b SEISMiC B study in early cardiogenic shock due to heart failure. The presentation was given at the Cardiovascular Clinical Trials Conference in Washington, DC.

Dr. Alexandre Mebazaa is Professor of Medicine at Université Paris Cité (France), Chair of Department of Anesthesia & Critical Care and an expert in heart failure and cardiogenic shock. He is part of the task force that wrote the 2021 ESC/HFA Guidelines of Heart Failure and the 2023 addendum.

WINT, new 52 low

WINT 10Q due 11/11

Took another position here, this could very easily be a $30.00 stock in 2 years, patience pays.

Ping pong .80s to $1s

This may be the bottom for a longer term play,if they are successful with phase three it will be a $30.00 +/- stock. IMO

WINT.....................................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783

WINT take smaller gain .94s to $1.20 exit having trouble on bigger breakout to $1.40s

1.11 test again

WINT $1.11 breakout solid and $1.44
Up next 3m floater

Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the issuance of an istaroxime patent for Japan. The patent is entitled, “Istaroxime-containing intravenous formulation for the treatment of heart failure (AHF).” The claims are directed to intravenous administration of istaroxime using increased infusion times alone or in combination with other agents useful to treat AHF, thereby improving treatment of heart failure and diastolic relaxation when compared to conventional protocols. The application has been accorded Patent No. 7560134 with a registration date of September 24, 2024 and will expire in 2039.

WINT new 52 week low

WINT new 52=week low

Yup they pr only to dilute there share pos?? Imo

Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the trial design of its SEISMiC Phase 2b has been published by the European Society of Cardiology Heart Failure. The article is entitled, “Safety and efficacy of up to 60 hours of intravenous istaroxime in pre-cardiogenic shock patients: Design of the SEISMiC trial.” It can be found online in Wiley Online Library DIO: 10.1002/ehf2.15102. Results can be viewed at https://ir.windtreetx.com/corporate-presentation. The Heart Failure Society of America also shared the results.

$1.26 + 36%

Pump it

WINT anew 52 week low

WINT under $2

Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock

WINT new 52 week low

On September 25, 2024, Windtree Therapeutics, Inc. (the “Company”) issued a press release announcing positive topline results from the Company’s Phase 2b SEISMiC Extension Study of istaroxime in treating early cardiogenic shock due to heart failure. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

WINT...................................................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783

There's a big borrowing fee. 50 dollars in losses per 1000 dollars of shorted shares per day.

FOR RESALE OF UP TO 27.7 MILLION SHARES BY THE SELLING STOCKHOLDERS - SEC FILING Source text for Eikon: Further company coverage:

Wow!!

My bad 10 million shares offering announced recently this won’t go anywhere. Share selling machine short it

Pop it to $5 already another 400k floater $3.85 resistance watch

Don’t blink

If you short 1000 dollars of shares you're now paying 70 dollars a day in fees,Up from 50 dollars of fees a few days ago.

Jumped from 700 percent to 800 percent borrow fee.

For the upcoming trading day on Friday, 6th we expect Windtree Therapeutics Inc to open at $3.05 and during the day (based on 14 day Average True Range), to move between $3.10 and $4.75, which gives a possible trading interval (+/-54.61%) up from last closing price. If Windtree Therapeutics Inc takes out the full calculated possible swing range there will be an estimated 109.21% move between the lowest and the highest trading price during the day.

Last week:First, the private placement delivers needed capital to support company operations, including the active Phase 2b clinical trial for istaroxime in cardiogenic shock. Second, the transaction fully converted and eliminated senior notes, including senior secured notes we used as bridge financing over the past several months eliminating this debt from our balance sheet.” 
Windtree shares are blasting higher on heavy volume Friday with more than 9 million shares

Borrow rates now 1500%!!!!!

Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced it has successfully completed enrollment in its SEISMiC Extension Phase 2b study of istaroxime in early cardiogenic shock caused by heart failure. The study is evaluating the ability of istaroxime to improve heart function and low blood pressure in the setting of early cardiogenic shock due to heart failure. The Company is looking to extend the positive results on these parameters as observed in the Company’s first SEISMiC Phase 2 clinical study that was previously reported. In addition, the Company hopes that the study results will substantiate the encouraging observations from the Company’s Phase 2 clinical study, indicating istaroxime has a favorable renal profile and does not increase cardiac arrhythmias. The SEISMiC Extension Study is utilizing longer dosing duration and tapering the dosing to assess the potential benefits.

Istaroxime is a novel first-in-class therapy that has demonstrated the ability to improve systolic contraction and diastolic relaxation of the heart while also increasing blood pressure and maintaining or improving renal function in patients with compromised cardiac function in three positive Phase 2 trials enrolling patients with acute heart failure (AHF). Cardiogenic shock is a serious condition that can occur when AHF patients continue to deteriorate and the heart cannot pump enough blood and oxygen to the brain, kidneys, and other vital organs. Mortality rates are significant and, depending on severity, range from 7% to 40% in the U.S. There is a lack of satisfactory pharmacological intervention to reverse the condition as available therapies have unwanted side effects such as risk for arrhythmias, decreased blood pressure, and renal dysfunction that limit their usefulness and position them as “rescue medicines” for severe cases. The cardiogenic shock worldwide total market value is estimated to be $1.25 billion per year.

RIP SHORTS! 50 dollars per 1000 dollars of share fee.